# Evaxion Becomes First Danish Company to Win International Prix Galien Award

> Evaxion won the 2026 International Prix Galien Award for AI-Immunology as best digital health solution, the first Danish company to take the prize.

- Published: 2026-10-30T08:18:15+00:00
- Section: Business
- Author: News Desk
- URL: https://newsforagent.com/news/2026-10-30/evaxion-international-prix-galien-award
- Source: [GlobeNewswire](https://www.globenewswire.com/news-release/2026/10/30/3392058/0/en/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution.html)

## Key takeaways

- Evaxion received the 2026 International Prix Galien Award for AI-Immunology as best digital health solution.
- CEO Helen Tayton-Martin and founder Andreas Holm Mattsson accepted the award at the American Museum of Natural History in New York City.
- Evaxion reported three-year phase 2 data for its personalized cancer vaccine EVX-01 at the ESMO Congress in Madrid the week before the award.

Evaxion A/S won the 2026 International Prix Galien Award for its AI-Immunology platform as best digital health solution, the first Danish company to receive the honor. [GlobeNewswire](https://www.globenewswire.com/news-release/2026/10/30/3392058/0/en/evaxion-receives-international-prix-galien-award-for-ai-immunology-as-best-digital-health-solution.html) reported the award on October 30, 2026.

## Evaxion's AI-Immunology Takes the Top Prize

[Evaxion](https://akta.pro/company-profiles/000059e/evaxion) is a clinical-stage Danish biotech that uses its AI-Immunology platform to design personalized cancer vaccines and prophylactic vaccines for infectious diseases. CEO Helen Tayton-Martin and founder and Chief AI Officer Andreas Holm Mattsson received the award at the American Museum of Natural History in New York City.

The International Prix Galien is presented every two years, and nominees must have won a national Prix Galien award within the previous two years. Evaxion won the Prix Galien UK Award for Best digital health solution in June 2026 and the Best Medical Technology/AI Advances award for the Nordic and high-growth European and Middle Eastern countries in December 2025.

"The International Prix Galien Award is a tremendous recognition of our science and technology, which we are honored and delighted to receive," Tayton-Martin said. "Having been refined, trained and enhanced for almost two decades, AI-Immunology™ is a leading and clinically validated platform for novel immune drug target discovery, especially in cancer vaccines."

Evaxion's furthest-developed candidate is its personalized cancer vaccine EVX-01. Three-year data from a phase 2 trial in advanced melanoma patients, reflecting durable clinical outcomes and immune system activation, was presented at the European Society for Medical Oncology Congress in Madrid the week before the award.

## Evaxion's Clinical and Funding Record

According to akta.pro [company records](https://akta.pro/company-data), Evaxion reported phase 2 data for EVX-01 in April 2026 showing an 86% target hit rate and a 75% objective response rate in advanced melanoma. The same records list total funding of $114.2 million and a cash position of $23.2 million at the end of 2025, with runway extended through the second half of 2027.

## How Evaxion Reached the International Stage

Evaxion reported a second-quarter 2026 net loss of $3.7 million, down 23% from $4.8 million a year earlier, Pulse 2.0 reported. Stock Titan reported that Evaxion held $14 million in cash at the time, sufficient to fund operations into the second half of 2027. In August 2026, Yahoo reported that Merck & Company disclosed a stake of 1,214,126 shares in Evaxion, following its September 2025 decision to in-license the vaccine candidate EVX-B3.

## What Comes Next for Evaxion

Evaxion's cash runway extends into the second half of 2027, according to the same records. The company's pipeline includes personalized and off-the-shelf cancer vaccine candidates and prophylactic vaccine candidates for infectious diseases, as described on [Evaxion's website](https://evaxion.ai).

## Companies in this story

- [Evaxion company profile](https://akta.pro/company-profiles/000059e/evaxion) · website: https://evaxion.ai

---
News for Agent · https://newsforagent.com/llms.txt